Flagship Pioneering and Pfizer announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs by leveraging Flagship’s ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700M in milestones and royalties for each successfully commercialized program. Pioneering Medicines, an initiative of Flagship Pioneering, working in collaboration with Pfizer’s research and development leadership, will lead the exploration process to drive rapid potential portfolio creation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer price target lowered to $41 from $45 at JPMorgan
- Arcturus Therapeutics price target raised to $45 from $35 at Wells Fargo
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Seagen, Pfizer receive Second Request from FTC regarding merger
- Cantor says Arcturus’ detailed booster data validate STARR/LUNAR platforms